BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 23350850)

  • 1. Antiviral activity of the interferon α family: biological and pharmacological aspects of the treatment of chronic hepatitis C.
    Scagnolari C; Antonelli G
    Expert Opin Biol Ther; 2013 May; 13(5):693-711. PubMed ID: 23350850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha.
    Alvarado Esquivel C; Elewaut A; Philippé J; Elewaut AE; Desombere I; Maertens G; Leroux-Roels G
    Rev Invest Clin; 2002; 54(1):41-50. PubMed ID: 11995406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Host factors and failure of interferon-alpha treatment in hepatitis C virus.
    Gao B; Hong F; Radaeva S
    Hepatology; 2004 Apr; 39(4):880-90. PubMed ID: 15057887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy.
    Balan V; Nelson DR; Sulkowski MS; Everson GT; Lambiase LR; Wiesner RH; Dickson RC; Post AB; Redfield RR; Davis GL; Neumann AU; Osborn BL; Freimuth WW; Subramanian GM
    Antivir Ther; 2006; 11(1):35-45. PubMed ID: 16518958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy-induced antibodies against the antiviral and antiproliferative effects of interferons in patients with chronic hepatitis C virus infection.
    Bálint E; Bakay M; Onody K; Farkas F; Horváth G; Tolvaj G; Dávid K; Horányi M; Béládi I
    Acta Microbiol Immunol Hung; 2004; 51(3):359-69. PubMed ID: 15571075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological basis for a proper clinical application of alpha interferons.
    Antonelli G
    New Microbiol; 2008 Jul; 31(3):305-18. PubMed ID: 18843884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-alpha/beta upregulate IL-15 expression in vitro and in vivo: analysis in human hepatocellular carcinoma cell lines and in chronic hepatitis C patients during interferon-alpha/beta treatment.
    Yamaji K; Nabeshima S; Murata M; Chong Y; Furusyo N; Ikematsu H; Hayashi J
    Cancer Immunol Immunother; 2006 Apr; 55(4):394-403. PubMed ID: 16041541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment.
    Chen L; Sun J; Meng L; Heathcote J; Edwards AM; McGilvray ID
    J Gen Virol; 2010 Feb; 91(Pt 2):382-8. PubMed ID: 19846672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon alfa subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls.
    Castelruiz Y; Larrea E; Boya P; Civeira MP; Prieto J
    Hepatology; 1999 Jun; 29(6):1900-4. PubMed ID: 10347136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Types of human leukocyte antigen and decrease in HCV core antigen in serum for predicting efficacy of interferon-Alpha in patients with chronic hepatitis C: analysis by a prospective study.
    Muto H; Tanaka E; Matsumoto A; Yoshizawa K; Kiyosawa K;
    J Gastroenterol; 2004 Jul; 39(7):674-80. PubMed ID: 15293139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained response with negative serum HCV-mRNA and disappearance of antibodies after interferon-alpha therapy in a kidney transplant recipient with chronic active viral hepatitis C.
    Luciani G; Bossola M; Muscaritoli M; Panocchia N; Ferrante A; Nanni G; Piccioni E; Tazza L; Grillo RL; Rossi Fanelli F; Castagneto M
    J Nephrol; 2003; 16(3):417-20. PubMed ID: 12832744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amino acid variations in hepatitis C virus p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis C.
    Mihm U; Grigorian N; Welsch C; Herrmann E; Kronenberger B; Teuber G; von Wagner M; Hofmann WP; Albrecht M; Lengauer T; Zeuzem S; Sarrazin C
    Antivir Ther; 2006; 11(4):507-19. PubMed ID: 16856625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-alpha therapy does not modulate hepatic expression of classical type I interferon inducible genes.
    Meier V; Mihm S; Ramadori G
    J Med Virol; 2008 Nov; 80(11):1912-8. PubMed ID: 18814253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telaprevir for the treatment of hepatitis C.
    Forestier N; Zeuzem S
    Expert Opin Pharmacother; 2012 Mar; 13(4):593-606. PubMed ID: 22332992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
    Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line.
    Zhu H; Zhao H; Collins CD; Eckenrode SE; Run Q; McIndoe RA; Crawford JM; Nelson DR; She JX; Liu C
    Hepatology; 2003 May; 37(5):1180-8. PubMed ID: 12717400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment response in chronic hepatitis C. Content of virus in serum is decisive for the outcome].
    Weiland O; Danielsson A; Lööf L
    Lakartidningen; 1998 Jan; 95(1-2):40-3. PubMed ID: 9458644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?
    Schaefer M; Heinz A; Backmund M
    Addiction; 2004 Sep; 99(9):1167-75. PubMed ID: 15317637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
    Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
    Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.